Challenges and advances in scale-up of label-free downstream processing for allogeneic cell therapies by Masri, Fernanda et al.
www.insights.bio
447
CELL & GENE THERAPY INSIGHTS
EXPERT INSIGHT
Challenges and advances in  
scale-up of label-free downstream 
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Recent advances in stem cell research and regenerative medicine are 
leading towards the realistic commercial prospect of more complex 
cell-based therapeutic products, offering the potential to revolutionize 
aspects of healthcare system. To date however, there are no truly ‘large-
scale’ cell therapy products available. To achieve successful commercial 
production, many factors come into play. To name a few; economics, ro-
bustness, reproducibility and, what this review is concerned about: scal-
ability. With cell therapies, a change in the processing environment may 
lead to a product change, which ultimately may be the difference between 
a successful batch (meeting product specifications) or a failed one [1]. To 
minimize process changes throughout the scales, processing steps must 
be carefully selected from an early stage. A particular challenge faced is 
that current ‘gold standard’ techniques for cell separation are not gen-
erally compatible with large scale processes. Dead-end batch centrifuga-
tion is a clear example of a process step that is heavily manual, difficult 
to automate while maintaining sterility, and limited in scalability [1]. The 
scope of this article is to explore and evaluate current and potential fu-
ture techniques for cell separation at large scale only.
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OVERCOMING DOWNSTREAM  
BOTTLENECKS IN CELL & GENE  
THERAPY MANUFACTURING
SCALABLE DOWNSTREAM  
PROCESSING FOR ALLO-
GENEIC CELL THERAPIES
Scale-up of cell manufacture can 
be achieved horizontally, through 
scale-out (serial production with 
multiple devices and/or production 
sites) and vertically, through scale-
up (increasing the volumetric or 
cell number throughput of a single 
device). On the one hand, scale-
out manufacture is likely to suffice 
for patient-specific therapies, such 
as many of the immunotherapies, 
or even rare diseases therapies, for 
which small production batches 
are needed. On the other hand, cell 
therapeutics that require scalable 
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manufacturing solutions are off-
the-shelf (allogeneic) therapies. 
These can encompass therapies such 
as those that use pluripotent stem 
cells (embryonic, mesenchymal or 
induced pluripotent stem cells), 
immortalized progenitors, or differ-
entiated cell populations. For these 
types of therapies, large scale can 
range anywhere from 50 L to a few 
hundred liters. In this review, when 
defining a technology as ‘capable 
of handling large scale’, it refers to 
a minimum of 50 L with potential 
of handling a few hundred liters. 
Moreover, the term ‘scalable’ is used 
to refer to technologies suitable for 
scale-up to address the allogeneic 
therapies’ needs. Scale-out sits out-
side of the scope of this review. 
To properly identify the potential 
of a downstream processing tech-
nique, we propose a series of pa-
rameters to be considered when as-
sessing the suitability for large-scale 
cell manufacture; namely whether 
or not its label-free, process mode 
(batch vs continuous), containment 
(closed vs open) and resolution (low 
vs high).
CURRENT CHALLENGES 
WITH TRADITIONAL DOWN-
STREAM TECHNIQUES FOR 
CELL-BASED THERAPEUTICS
Cell-based products create new 
challenges for large scale produc-
tion and processing, necessitating 
a re-think of current manufactur-
ing strategies. With these therapies, 
the end products (i.e., the cells 
themselves) are defined by their re-
spective manufacturing process [1]. 
Therefore, exposure to mechanical 
and physiochemical stresses during 
processing can ultimately lead to 
a change in identity of the end 
product. To add to the challenge of 
maintenance of identity throughout 
processing and scales, there is also 
the number of cells required for a 
therapeutic effect.
The number of cells that com-
pose a clinically relevant dose will 
differ for varying therapies. For 
instance, a clinically relevant dose 
of human pluripotent stem cell 
(hPSC) derived cardiomyocytes for 
myocardial infarction is estimated 
at 1x109 cardiomyocytes [2], which 
is similar to that estimated for bone 
marrow-derived mesenchymal stro-
mal cells (MSCs) for graft-versus-
host disease (GvHD) [3]. On the 
other end of the scale, a single unit 
for red blood cell transfusion re-
quires approximately 1012 cells. This 
means that a single dose requires the 
production of 200 L at a density of 
5x107 cells mL-1 or, if one were to 
control the final volume to some-
thing less risky and more manage-
able, such as 5 L, this would require 
a final cell density of 2x1011 cells 
mL-1. Both scenarios present chal-
lenges for traditional downstream 
processing systems. Processing 200 
L of cells with current technologies 
can take hours, compromising cell 
health by holding the cells prior- 
and post-processing which can lead 
to increased cell death [4]. Process-
ing a smaller volume with very high 
cell density (i.e., highly viscous cell 
suspension) will inevitably be hard-
er to handle. 
Another key consideration in the 
manufacturing of any cell-based 
product is its purity and the degree 
of contaminant removal needed. In 
the case of stem cell-derived thera-
peutics, this encompasses freedom 
from unknown or adventitious 
pathogens, maintenance of cell 
quality attributes, removal of ad-
ditives and secreted products from 
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the expansion phase, through to the 
homogeneity of cell populations. 
Ensuring cellular homogeneity is 
key throughout a manufacturing 
process to ensure robustness and 
reproducibility of protocols as well 
as purity of the intended end prod-
uct. Regardless of whether the prod-
uct is intended to be used in vitro 
(discovery or screening) or in vivo 
(for transplantation to treat a spe-
cific indication), homogeneity will 
remain a key target in the product 
specification to ensure efficacy and 
reproducibility. Moreover, a critical 
concern for cell therapies will be the 
absence of undifferentiated cell pop-
ulations in the final cellular product 
intended for transplantation. These 
cells have the potential to form ter-
atomas: benign tumors capable of 
interfering with tissue physiology, or 
worse, teratocarcinomas with meta-
static potential. Consequently, there 
exists a pressing manufacturing need 
for effective separation technologies 
that can meet the stringent target 
criteria. 
DOWNSTREAM  
PROCESSING  
METHODOLOGY DESIGN
Development of downstream pro-
cessing technologies suitable for 
cell manufacture must balance 
the requirements of the intended 
product (e.g., composition, purity, 
cell quality attributes, etc.), as well 
as the demands of the process as 
a whole (e.g., sample preparation 
and handling, running costs, ease 
of operation, skilled personnel re-
quirements, Good Manufacturing 
Practice compatibility, etc.). 
With this in mind, the mode 
of operation and methodology 
employed can become crucial in 
designing a suitable manufacturing 
strategy. Due to the varied nature 
of cell therapy products, different 
desirable traits will be key for some 
type of products and may not nec-
essarily be as key for others. This 
section will discuss some consider-
ations that should be taken into ac-
count when choosing downstream 
processing steps for any allogeneic 
cell therapy workflow (Figure 1). 
This in turn will help the reader un-
derstand the motivation behind the 
methodologies underlying available 
techniques (presented in the follow-
ing section) and make an informed 
decision on which traits to prioritise 
in order to meet the specifications 
of the therapy of interest.
Label versus label free 
downstream processing
Labeling methods are those that rely 
on a tag for separation. Separation 
may be positive (where the cell of 
interest is the main target either by 
carrying the label, or by being tar-
geted by a component carrying the 
label), or negative (where the cell of 
interest is not the main target and 
the label aims to retain a different 
component). 
The two main cell separation 
methods that rely on labeling and 
are widely used for research and 
clinical practices are flow cytomet-
ric fluorescent-activated cell sorting 
(FACS) and magnetic activated cell 
sorting (MACS) technologies. Fluo-
rescent- and magnetic-activated cell 
sorting methods are based on the 
recognition and labeling of cell-as-
sociated epitopes located inside or 
on the surface of cells. Detection 
normally relies on targeted epitopes 
using high-affinity probes including 
antibodies, peptides or nucleic acids 
directly or secondarily labeled with 
photo-excitable and light emitting 
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molecules or nano- or micro-sized 
particles. These techniques have 
proven very useful for a variety of 
applications and have the potential 
to yield highly pure cell populations 
(>95%). However, cell labeling 
adds process time and costs, and 
the success of high affinity labeling 
is dependent on the strength and 
exclusivity of expression of the tar-
geted epitope used to discriminate 
cell populations. In addition, in the 
case of positive selection, labels may 
need removal depending on applica-
tion, and incomplete label removal 
may have implications for therapeu-
tic use. But even in the case of nega-
tive selection, label-requiring meth-
ods may not be optimal for many 
clinical applications, as antibodies 
and labels (dyes, magnetic particles) 
have been introduced into the sam-
ple at the start of the procedure, and 
may still be present in the enriched 
and depleted cell fractions. 
Although label-requiring down-
stream methods are clearly a key part 
of future cell therapy manufacture, 
the demand for cell selection tech-
niques more compatible with large-
scale clinical application has resulted 
in the development of a variety of la-
bel-free cell separation technologies, 
explored in this review. For the pur-
pose of this review, only label-free 
technologies will be assessed. The 
authors believe that label-free tech-
niques have scope for scale-up whilst 
labeling technologies may be more 
suitable for small batches and pa-
tient-specific therapies. 
Whilst label-free techniques do 
not present the above-described 
drawbacks, utilizing cell biochem-
ical or biomechanical properties 
(e.g., size, polarity, charge, elasticity 
 f FIGURE 1
Summary of desirable traits for downstream processing techniques.
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or deformability), may not be spe-
cific enough and can result in com-
promised cell purity, selectivity and 
yield. 
Label-free downstream tech-
niques currently in research or un-
der development are mostly either 
derived from the field of biomicro-
fluidics (and have thus far primarily 
been designed for small-scale use 
like cancer diagnostics and drug 
monitoring rather than large-scale 
cell separation for therapeutics) or 
are adapted from unit operations 
more traditionally used in protein 
therapeutics (and therefore may not 
be sufficiently tailored to cellular 
targets to offer selectivity). To of-
fer significant progress in this field, 
new techniques should aspire to be 
easily scalable whilst offering im-
proved selectivity.
Low versus high resolution
Resolution refers to the capacity of 
the downstream processing platform 
to distinguish the cell of interest 
from the remaining components. 
Different techniques will offer vary-
ing degrees of resolution. Ultimate-
ly, the resolution requirements for 
the downstream platform will be 
largely dictated by the nature of the 
starting population. Low resolution 
might suffice if the starting popula-
tion consists of distinctly different 
cells (as would be the case e.g., for 
red blood cell or plasma products), 
while populations made up of very 
similar cells or containing rare cells 
would demand high resolution (e.g., 
selection or removal of hematopoi-
etic stem cells and cancer cells).
Containment 
Containment (open or closed) re-
fers to the extent to which cells are 
exposed to ambient environments. 
A ‘closed’ environment is limited 
by the boundaries of the vessel or 
device the cells are contained in. 
While these boundaries may be gas 
permeable, they otherwise consti-
tute barriers to pathogens or other 
non-gas permeable contaminants in 
the atmosphere. Open systems will 
require the use of regulated envi-
ronments (i.e., laminar flow hoods, 
‘clean rooms’) that control and lim-
it airborne contaminants below that 
normally detected in ambient at-
mosphere. Creating, operating and 
maintaining such environments is 
very costly, and increases signifi-
cantly with scale, but are essential 
to comply with regulatory stan-
dards. Environmental specifications 
for operators of closed systems are 
substantially lower, thereby reduc-
ing costs and risk of contamination 
to the final product.  
Batch versus continuous 
separation
Batch operation is when there is a 
defined start and end to a process, 
whereas continuous is when pro-
duction is on-going and the prod-
uct is constantly being produced. A 
key advantage of batch processing is 
the ability to accurately distinguish 
the start and end of the production 
of a batch, which is desirable from 
a regulatory perspective. However, 
often batch processes require one 
or more ‘hold’ steps to match pro-
cessing times to equipment, which 
is non-ideal for cell therapy prod-
ucts. Every batch has to be tested 
and qualified to ensure inter-batch 
reproducibility and for safe product 
release. Quality control (QC) tests 
can often be expensive (generally 
due to the expensive nature of the 
product being tested) and lengthy, 
and generally the product cannot be 
used until QC results are satisfacto-
ry for safe release.
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Continuous production allows 
for larger amounts of product being 
manufactured, and thus is prefera-
ble for allogeneic therapies. Where-
as it becomes less clear with respect 
to QC testing, if the production 
can be validated to meet product 
specifications for a given period of 
time, then QC burden diminishes. 
However, there’s an inflection point 
at which the risk associated with 
something going wrong during pro-
cessing outweighs the benefits of 
continuous production. 
Scalability
Of particular interest in cell therapy 
development are separation meth-
ods that may lend themselves to 
large-scale production, particularly 
through scale-up. Easily scalable 
separation techniques will become 
more and more important as regen-
erative medicine develops, and par-
ticularly as allogeneic therapies be-
come more common. Moreover, the 
development of bench-scale tech-
nologies that better mimic the full 
scale will be paramount to the rapid 
development of robust downstream 
processes and allow cost-effective 
process optimisation [5]. Many of 
the currently applied downstream 
processing techniques, whilst highly 
effective in terms of cell isolation, 
are limited by the need to label tar-
get cells to effect isolation and by a 
limited maximal scale of operation. 
Downstream processing 
step positioning
A further driver for methodology 
selection is where in the process 
workflow to implement the re-
quired downstream manufacturing 
process. Unlike more traditional 
biotherapuetic processes, it may not 
be necessary, or even optimal, to 
purify at the end of the process, but 
rather to consider purification steps 
at key points. For instance, if the 
challenge is removal of pluripotent 
cells from the product, a purifica-
tion step immediately after lineage 
commitment during a differentia-
tion may be simpler and could cer-
tainly be carried out at smaller scale 
than a step at the end of expansion 
phase post-commitment.
CURRENTLY DEVELOPED 
DOWNSTREAM  
PROCESSING TECHNIQUES
In this section, a selection of reported 
downstream processing techniques 
potentially suitable for allogeneic 
large-scale clinical production are 
considered. Only label-free tech-
nology that can be scaled-up, or has 
the potential to do so, will be re-
viewed. For each separation method 
the underlying technical principle 
is described, followed by discussion 
of the above listed selection criteria. 
Techniques that do not meet all the 
selection criteria (such as spinning 
membrane filtration and others) 
will not be reviewed.
Field flow fractionation 
separations
This category of separation tech-
niques look to use waves or fields 
to create landscapes that drive cells 
to migrate to certain points, based 
upon key properties of the cells. In 
general, these methods combine 
a laminar flow with a perpendic-
ular, axial radiation force to create 
field-driven separation. 
In terms of scale-up, all field 
flow fractionation (FFF) systems 
present similar challenges: the sep-
aration is 1D and therefore gener-
ally constrained in throughput. The 
development of 2D and 3D fields 
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overcome this challenge and are the 
predominant features in the most 
recent techniques developed (dis-
cussed below).
Acoustophoresis
Acoustophoretic sorting separates 
cells based on cell size, density and 
compressibility. It is a label-free 
method that employs the interac-
tion between the acoustic radiation 
force exerted by an ultrasonic stand-
ing wave and the fluid drag force 
on the cell. The acoustic radiation 
force will result in the particle mov-
ing toward either the pressure node 
or antinode of the ultrasonic waves, 
depending on the size of the cell and 
its deformability (determined by 
both the cell and fluid density and 
compressibility). Acoustophoresis 
has been described as a gentle sep-
aration method with no apparent 
acute adverse effects for the cells due 
to exposure to ultrasound, including 
possible non-thermal effects due to 
cavitation ([6] and references there-
in). The reported separation resolu-
tion is high, and can be optimized 
for required cell type by adjusting 
operating settings (Figure 2). 
Acoustophoretic sorting devices 
had traditionally been developed as 
small, microfluidic platforms, not 
amenable to high throughput un-
less operated in parallel. Moreover, 
increasing sample flow rates in an 
attempt to increase throughput per 
device reportedly reduced recovery 
efficiency [7]. However, recent prog-
ress has seen the appearance of a 
couple of commercial acoustopho-
retic separation technologies – one 
from Applikon® Biotechnology and 
 f FIGURE 2
Principle of acoustophoresis. 
Cross-sectional view of acoustic focusing
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(Top) Cross-sectional view of cell distribution in the microchannel without ultrasound (left) and with ultrasound forming an ultrasound 
standing wave (right); (bottom) Illustration of acoustophoresis chip (reprinted from [4]).
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one from FloDesign. These technol-
ogies are used as perfusion devices 
in stirred tank reactors as well as for 
downstream processing (cell wash-
ing and concentration). BioSep 
(Applikon® Biotechnology, Nether-
lands) uses SonoSep’s acoustic wave 
separation technologies, based on a 
planar standing wave. Whereas most 
reported findings show promising 
results with CHO and insect cells 
[8], available literature for cell ther-
apy applications is limited. For the 
SonoSep device, the cells are held 
by in the chamber during perfu-
sion, whilst a harvest flow is drawn 
through to the waste. The range of 
application for perfusion purposes 
spans from 1 to 1000 L, yet its scal-
ability with respect to downstream 
processing applications may not be 
as comprehensive. The size of the 
chamber becomes the bottleneck as 
it can only hold so many cells be-
fore they start aggregating due to 
cell–cell contact. 
The newer generation of this 
technology is the FloDesign Sonics 
device (FloDesign Sonics, USA), 
which uses a multidimensional 
standing wave instead of a planar 
one. The 3D field acts as a mem-
brane; similar methodology to cross-
flow filtration but without the use of 
a physical membrane. This particu-
lar device is used for perfusion and 
cell concentration. In the perfusion 
mode of operation, the acousto-flu-
idic interaction mimics that of tan-
gential flow filtration, where the 
acoustic radiation force prevents 
the cells from entering the acoustic 
field and thus return to the biore-
actor or other culture vessel. The 
range of applications for perfusion 
purposes spans from 0.25 to 100 
L. For concentration, the cells are 
trapped in the standing wave, allow-
ing up to 40x109 cells at flow rates 
of 2 L every hour to be processed. 
The particular set-up explained for 
the perfusion mode allows for much 
faster flow rates of media or buffer 
exchange and does not present the 
same problem with the chamber 
size being the limiting factor for the 
downstream processing, as the pro-
cess is taking place in-situ (whether 
it is a culture vessel or a hold tank). 
The concentration mode is carried 
in the chamber to achieve high cell 
densities in a small volume.
Dielectrophoresis
Dielectrophoresis (DEP) selects 
cells based on a variety of param-
eters, including size, shape, cytosol 
conductivity, polarizability and 
membrane properties like perme-
ability, capacitance and conduc-
tivity. DEP-based separation is a 
label-free method whereby an elec-
tric force is exerted on dielectric 
particles, including cells suspend-
ed in a non-uniform electric field. 
The strength of this exerted force 
is dictated by properties of not 
only the cells but also the media, as 
well as the frequency of the electric 
field, and dictates whether a cell 
is attracted to or repelled by the 
charged electrode. Adjustment of 
the DEP force field can be obtained 
through an abundance of tunable 
factors, allowing manipulation of 
the cells according to various cell 
intrinsic properties. The technique 
has been used to separate a variety 
of mammalian cell types, including 
cancer cells [9], infected red blood 
cells [10] and undifferentiated 
pluripotent stem cells from their 
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differentiated progeny [11,12]. 
Though DEP has been successful-
ly integrated into a commercially 
available cell selection technology 
(i.e., ApoStream®, from ApoCell), 
this system is currently being used 
to select rare cells (e.g., circulating 
tumor cells) from a population, 
so distinct from separation in the 
context of a cell production pro-
cesses. Indeed, a number of bottle-
necks have been raised that likely 
prevent scalable DEP-based sepa-
ration platforms for cell manufac-
ture. Heating near the electrodes 
due to media conductivity may 
result in bubbles and heat-induced 
cell death, or the generation of free 
radicals. Additionally, the strong 
dependency of DEP on cell size 
means that inter cell-type size vari-
ation may override cell type specific 
differences, reducing the relevance 
of the technique. The latter hurdle, 
however, might be overcome with 
isoelectric DEP, where sorting is 
mainly dependent on the dielectric 
properties rather than size by using 
a media conductivity gradient [13]. 
Potentially, DEP could be part of a 
closed, continuous, cell separation 
platform that could achieve large-
scale selection through scale-out 
rather than scale-up, by placing 
multiple devices in parallel. 
Optical landscapes
Optical sorting of cells is a tech-
nique based on cell size and re-
fractive index using an optical 
force. Depending on the type of 
optical sorting method, cell label-
ing is essential, or optional, merely 
enhancing selectivity. Dholakia 
et al. call the former active, and 
the latter passive optical sorting 
[14]. We will not delve into active 
sorting, as it requires a label and 
therefore is outside of the scope of 
this review. Passive optical sorting 
can be achieved with optical twee-
zers [15], optical chromatography 
[16] or optical energy landscapes 
[17]. Optical tweezers use radia-
tion pressure from a focused laser 
beam to trap and move cells, while 
optical chromatography employs 
the balance of fluidic and optical 
forces on a particle in a channel 
with a flow of fluid in the opposite 
direction of a laser beam. Optical 
energy landscapes use the interfer-
ence of two or more laser beams 
to generate an energy landscape, 
and utilize variation in shape, size 
and refractive index to induce 
separation movement in different 
populations within the landscape. 
Though optical sorting has been 
used successfully to separate dis-
tinct mammalian cell populations 
[17,18], this can only be achieved 
when the differences in size and 
refractive index of the various 
populations is large enough [19]. 
Moreover, separation efficiency 
might be compromised due to the 
fact that a cell could have differ-
ent refractive indexes depending 
on the position or state of its var-
ious components. To date, optical 
separation in literature has been 
achieved only with small-scale de-
vices. However, the development 
of larger scale and 3D optical 
landscapes is a focus of current 
research, and this approach may 
render the methodology suitable 
for adaption to larger scale down-
stream processing techniques, 
particularly if power consumption 
can be addressed.
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Centrifugal techniques
Centrifugal separation of cells is far 
from a new concept. To date, the 
cell therapy industry workhorse is 
the swing-bucket rotor centrifuga-
tion (batch dead-end centrifuga-
tion), which has proven to be diffi-
cult to automate and -as it stands- is 
not a scalable solution [1]. For this 
reason, it falls outside of the scope 
of this review. However, the under-
lying principle of centrifugation has 
been used in the design of novel cell 
processing methodologies and in-
tegrated automated platforms that 
combine centrifugation and filtra-
tion. Centrifugal separations em-
ploy size and density variations to 
achieve separation, driven by cen-
trifugal acceleration. 
Centrifugal counterflow 
elutriation 
Centrifugal counterflow elutriation 
(CCE) involves cells in a conical 
centrifugal chamber being subject-
ed to centrifugal forces in an out-
ward direction and a fluid force in 
an inward direction. It  exerts gentle 
force on the cells, making it an at-
tractive downstream processing op-
tion (Figure 3). 
Since its introduction in the 
1970s, CCE has been used routine-
ly for research purposes, and later 
also for clinical procedures, includ-
ing plasmapheresis and the collec-
tion of particular white blood cells 
and stem cells [20–25] from apher-
esis products. Commercially avail-
able CCE platforms include the JE-
5.0 Elutriation System (Beckman 
Coulter, USA), Elutra© Cell Sep-
aration System (Terumo BCT, 
UK) and kSep® Systems (kSep400, 
kSep6000S and beta testing smaller 
sized unit for process development, 
from Sartorius Stedim, UK). With-
in these platforms CCE is already 
part of an automated, closed, inte-
grated cell separation process capa-
ble of washing and then separating 
large batches of heterogeneous cell 
populations. For example, the ca-
pacity of Elutra© processing cham-
ber is 3  x  1010 white blood cells, 
while the kSep6000S is able to sepa-
rate up to 1200 x 109 cells at 10–50 
x 106 cells mL-1 in a single use, fully 
closed, automated GMP-compat-
ible platform. Whether CCE, and 
these commercially available sys-
tems in particular lend themselves 
equally well for the separation of 
undifferentiated pluripotent stem 
cells from their in vitro differentiat-
ed progeny needs to be determined. 
With these technologies capital 
cost can be high, but one machine 
can potentially accommodate a 
large range of production scales, 
which may make a strong case for 
investment. 
Centrifugation itself is relative-
ly easily scaled, and as such should 
present a strong case for incorpora-
tion in large scale downstream pro-
cessing for allogeneic cell therapies. 
There are, however, two challenges 
to this. Firstly, CCE is not strictly 
a continuous centrifugation opera-
tion. The necessity of maintaining 
the density gradient within the sep-
arating chamber means that larger 
scale requires larger chambers, not 
increased continuous throughput, 
and this rapidly becomes prob-
lematic from a rotational stability 
point of view. Furthermore, as the 
size of the device increases, physi-
cal shear forces on the cells during 
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introduction increase, running 
the risk of damage to sensitive cell 
products.
Continuous centrifugation with 
flexible diaphragm
During centrifugation, the flexi-
ble diaphragm located inside the 
centrifuge bowl can be inflated with 
hydraulic fluid. As the diaphragm 
inflates, it presses against the bot-
tom of the cell processing bag giv-
ing these techniques the capacity 
to express fluids and/or cells for re-
moval or collection during centrifu-
gation. Two commercially available 
 f FIGURE 3
Principle of centrifugal counterflow elutriation.
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3
(1) Cells suspended in medium are pumped into the chamber. (2) Centrifugal sedimentation of cells is balanced by flow velocity. (3) Flow 
increased- smaller, slow sedimenting cells elutriate out of the chamber. 
Image provided courtesy of Beckman Coulter. Image copyright ©2014 Beckman Coulter.
Label
Label-free
Open
Closed 
 

Batch Low resolution
High resolutionContinuous


CELL & GENE THERAPY INSIGHTS 
458 DOI: 10.18609/cgti.2017.041
automated centrifuge systems for 
blood component processing are 
the TACSI® PL and the COBE® 
2991 Cell Processor (Terumo BCT, 
UK).
TASCI® PL (Terumo Automated 
Centrifuge and Separator Integration 
System for Platelets) is a closed, inte-
grated manufacturing system that can 
process up to six buffy-coats at a time 
into platelet concentrate by first pool-
ing and centrifugation of the buffy 
coats followed by pump-operated 
filtration for separation and leukore-
duction of the final platelet product. 
Reports show that the system, which 
is used most commonly in blood cen-
ters, achieves efficient platelet recov-
ery [26] suitable for clinical use [27].
The COBE® 2991 Cell Processor 
contains a centrifuge with a flexible 
diaphragm and separates components 
based on specific gravities. It is an in-
tegrated system whereby a hydraulic 
fluid presses against a flexible mem-
brane to express fluid or cells into an 
attached collection bag. It is a versatile 
system that can be used for blood and 
cell sample washing, volume reduc-
tion of cell products and cell concen-
tration. For specific cell selection pur-
poses, for example human pancreatic 
islet isolation, however, it does not 
seem to improve on manual density 
gradient purification [28]. 
In terms of scalability and engi-
neering challenges, these systems are 
similar to the CCE approach de-
scribed previously. However, it should 
be easier to develop a continuous ver-
sion of a centrifuge/filter system, po-
tentially simplifying scalability.
Hydrodynamic-type 
techniques
Broadly, these types of separation 
methodologies rely on flow behav-
iors to separate cells according to 
various properties. Here we have 
loosely grouped them, although 
individual techniques rely on differ-
ing effects to drive separation.
Deterministic lateral 
displacement
Deterministic lateral displacement 
(DLD) is a label-free, passive tech-
nique that separates cells according 
to size and deformability (Figure 4). 
DLD is a continuous separation 
process based on asymmetric bifur-
cation of a laminar flow around ob-
stacles (micropillars), with particles 
above a critical size being bumped 
laterally from the original streamline 
[29]. Although DLD’s simplicity is 
attractive, and DLD cell separation 
achieves good size resolution [30] 
and high enrichment [31], clogging 
of the device could be an issue for 
its implementation in an integrat-
ed, closed separation platform for 
cell manufacture. This is particular-
ly likely to be the case in a sample 
containing large ranges of cell sizes, 
as DLD devices tend to be inacces-
sible to particles significantly larger 
than their chosen separation diam-
eter. However, reducing the pillars 
to point-like obstacles (thus reduc-
ing fluidic resistance) may improve 
throughput [32]. Furthermore, DLD 
is still attractive as a final “polishing” 
step where contaminants may be 
low in number and similar in prop-
erties to target cells.
Potentially DLD could be scaled 
up, but there are manufacturing 
challenges in constructing large 
micropillar arrays and significant 
problems with blockages. 
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Hydrodynamic filtration
Hydrodynamic filtration (HDF) 
selects cells according to size and 
shape [33]. HDF is a method where-
by cells in a continuous flow are 
separated based on their flow pro-
file as dictated by their size, which 
subsequently affects their proxim-
ity to the channel wall. HDF de-
vices contain a main flow channel 
with a number of sideway collec-
tion outlets. Smaller cells (which 
will flow closer to the channel side-
wall than larger cells) will enter the 
outlets earlier, and are thus the first 
to leave the channel. Separation is 
based purely on cell flow profile 
and not channel geometry. This 
means channels can be a lot larger 
than the cells, reducing clogging 
and increasing throughput, which 
is theoretically advantageous for 
scalability. The main drawback is 
that laminar flow profiles must be 
maintained, which becomes more 
challenging with larger diameters. 
The method has been used success-
fully to separate various cell types, 
including leukocytes [33] and liver 
cells [34] and, using HDF devices 
with curvilinear geometry to add 
Dean drag force, blood cells from 
plasma and white blood cells from 
red blood cells [34]. HDF devices 
achieve high separation efficiencies 
 f FIGURE 4
Principle of deterministic lateral displacement.
1  2  3
1  2  3
1  2  3
1  2  3
G
d λ
Post
Streamlines
Large particleSmall particle
Schematic illustrating the separation by deterministic lateral displacement in an array of microposts, with an example row shift fraction 
of a third. This shift creates three equal flux streamlines. The dashed lines are the boundaries between the streamlines, which are 
assigned an index in the gaps between the posts. Paths of particles both smaller and larger than the critical threshold are depicted with 
green and red dotted lines respectively. Small particles stay within a flow stream and large particles are displaced at each obstacle. G 
is the clear spacing between the gap, ƛ is the center-to-center post separation, and d is the relative shift of the post centers in adjacent 
rows. Reproduced from [30]. Copyright (2006) National Academy of Sciences, USA. 
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of 95% [35] at high throughput 
rates ranging from 2 x 105 to 1 
x 106 cells min-1 [34,35]. To date, 
devices are small scale and are be-
ing optimized for point-of-care 
applications rather than large-scale 
manufacturing [35].
Inertial migration
Inertial migration is a size-based 
cell separation method. A label-free, 
active technique that makes use of 
intrinsic hydrodynamic forces (Fig-
ure 5) [36–39]. 
Two types of inertial migration 
devices have been designed, consist-
ing of circular pipes and/or spiral 
channels (asymmetric curvilinear 
channel). In both designs, cells are 
focused thanks to the balance of 
two inertial lift forces (known as 
‘tubular pinch effect’): shear gradi-
ent lift; and wall effect lift. In the 
curved-channel design, Dean drag 
force is added as a third force, al-
lowing multi-size separation. As a 
result, cells of a particular size are 
focused in a unique equilibrium po-
sition, generating distinct particle 
streams, which are collected in sep-
arate outlets at the end of the chan-
nel. Separation efficiency of this 
technique is inherently linked to 
cell population size heterogeneity. 
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 f FIGURE 5
Principles of inertial migration.
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Schematic of spiral microparticle separation. The randomly dispersed particles equilibrate at different equilibrium positions along the 
inner wall (IW) of the spiral microchannel under the influence of lift force and Dean drag force. Separation between individual particle 
streams is enhanced by opening the spiral channel into a wider straight channel before extracting the individual streams using a multiple 
outlet design. Reproduced from [37] with permission of The Royal Society of Chemistry.
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It has been shown to reach 80% 
separation when used to distinguish 
two types of neuronal cells, neu-
roblasotoma and glioma cells [36]. 
Due to its relatively simple design, 
the technique can be implemented 
as a closed, integrated platform for 
continuous cell selection. Similarly 
to HDF, the channel width can be 
much larger than the cell sizes, al-
lowing high volumetric flow rates 
(>106 cells min-1), while reducing 
the chance of clogging.
Jung et al. have developed vari-
ous multi-orifice flow fractionation 
(MOFF) devices for continuous cell 
separation, which utilize inertial lift 
and momentum-change-induced 
inertial force generated in a series of 
contraction/expansion microchan-
nels, and show they can be used to 
efficiently select rare cells from blood 
samples (e.g., circulating tumor 
cells). However, to date, these devic-
es have not been reported for use in 
large-scale cell separation [40,41].
Filtration-based techniques
Filtration techniques are well estab-
lished within the pharmaceutical 
industry and therefore there is a lot 
of expertise around this topic. The 
most common types of filtration are 
normal flow filtration (otherwise 
known as dead end), tangential flow 
filtration (or cross flow) and spin-
ning membrane filtration. Spinning 
membrane filtration techniques are 
outside of the scope of this review, 
given that they are not amenable to 
large-scale manufacturing. 
Filtration principles generally 
rely on differences in size for sep-
aration, which limits the ability to 
highly resolve cell populations, as 
heterogeneity of cells usually means 
that the size range of cells of a single 
type overlaps any difference in siz-
es between cells of different types. 
However, recent progress has seen 
elastic modulus and other param-
eters used as well as size to affect 
separation, and in some specific ap-
plications (such as blood fraction-
ation), size alone may be an effec-
tive separation parameter.
Normal flow filtration
Normal flow filter devices contain 
small filters (sieves) with pores or 
holes to selectively capture cells 
based on size and deformability. 
Since these devices are not reliant on 
an external force or cell labeling, they 
can be used as a simple dead-end fil-
ter, trapping unwanted cells. As a 
consequence, the method works best 
if the percentage of unwanted cells is 
relatively low, so as not to clog the 
filter too quickly. In addition, clog-
ging of the pores may result in flow 
irregularities. The platform has been 
used for research and diagnostics in 
the cell therapy area (e.g., trapping of 
rare circulating cancer cells) but not 
for (large-scale) cell production for 
the clinic. However, normal flow fil-
tration (NFF) for cell removal is rou-
tinely used at very large scale in the 
manufacture of protein therapeutics 
from mammalian cells, so clearly 
there is scope for NFF to work as a 
scalable technique.
In general, NFF would only be 
suited for negative selection pro-
cesses, and then only when seeking 
to remove larger contaminating 
cells from smaller target cells, but 
may present an interesting opportu-
nity in some processes, particularly 
as a more crude early-stage separa-
tion technique.
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Tangential flow filters 
Tangential flow filters (TFF; also 
known as cross-flow filters or mem-
branes) select cells based on size and 
deformability during laminar flow 
migration through porous mem-
branes or other filtration arrays (Fig-
ure 6). The name derives from the 
path the fluid follows in this flow, 
namely tangentially across the sur-
face of the filter rather than into the 
filter. Whereas larger cells may clog 
a normal flow filter, in TFF, these 
can be washed away during the 
filtration process, delaying prob-
lems with fouling and increasing 
the length of time the filter can be 
functional. Furthermore, cells or 
particles retained in a TFF system 
(the retentate) remain in solution 
and therefore do not need a resus-
pension step, which has been shown 
can lead to damage [42]. Thus TFF 
is usable as a positive and negative 
separation tool.
The technique has been used 
to isolate and enumerate cancer 
cells from blood (isolation effi-
ciency >80% by [43]), for blood 
separation (e.g., >95% red blood 
cell removal by [44]), and to recov-
er >97% plasma selectivity when 
separating plasma from whole 
blood [45]. However, the reported 
devices are microscale, and sam-
ples require rigourous dilution 
(>50 times [44]) prior to separa-
tion. Zhang et al. describe in their 
proof-of-principle paper success-
ful separation of two cancer cells 
with different deformability us-
ing a TFF chip device, but with 
limited efficiency (the fraction of 
the more elastic cells increased 
from 50 to 73%). Willoughby et 
al. reported similar results when 
separating pluripotent and dif-
ferentiated osteoblastic cells, and 
pluripotent cells and fibroblasts 
[46,47]. A study comparing vari-
ous silicon-based microfilters to 
separate white blood cells from 
red blood cells indicates that TFF 
is superior over NFF and weir and 
pillar type filters [48]. TFF sys-
tems are commonly operated at 
large scale in the mammalian and 
 f FIGURE 6
Principle of tangential flow filtration.
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bacterial cell culture industries 
and several companies produce 
large-scale TFF membranes suit-
able for handling mammalian cell 
material. 
At a larger scale, the use of TFF 
as a continuous, integrated alter-
native techniques for the wash-
ing and concentration of human 
mesenchymal stem cells (hMSCs) 
has been reported [49]. Using this 
technique, Cunha and colleagues 
[49] showed high protein clearance 
(98%), and high recovery of viable 
hMSCs (70%) with no impact on 
cell viability (95%) or other CQAs 
(morphology, immunophenotype, 
proliferation, adhesion capacity 
and multipotent differentiation 
potential). Furthermore, these 
studies show shorter processing 
times when using continuous fil-
tration techniques as opposed to 
discontinuous operations. As is 
clearly portrayed in Cunha’s re-
port, care must be taken during 
scale-up to ensure that shear levels 
within the flow path of the mem-
brane systems remain low enough 
to not adversely affect cells.
Simple versions of TFF separa-
tions can be seen in weir and pil-
lar type devices, which force cells 
past obstacles to separate on the 
basis of size and deformability, as 
above. Both weir-and pillar-type 
filters have been reported as part 
of a continuous flow device [50]. 
So far studies on fractionating 
whole blood report low flow rates 
and limited efficiency and a study 
by Ji et al., comparing TFF, NFF, 
weir-type filters and pillar-type 
filters for the separation of white 
blood cells from red blood cells 
showed TFF as being more ef-
ficient that the latter three [48]. 
Weir-type and pillar type filters 
may thus be more suited for small 
scale applications, for example 
obtaining a relatively low number 
of particular cells for downstream 
analysis rather than large-scale cell 
production processes.
Expanded bed 
chromatography
Expanded bed chromatography 
(EBC) is another well-established 
downstream technique. Its use for 
cell therapies has been limited yet 
promising. Cunha et al. have re-
ported successful use of negative 
mode EBC, with a multimodal 
prototype matrix based on core-
shell bead technology, for hMSC 
downstream processing [50]. The 
study reports an expanded bed 
with a stable and characterized 
matrix using standard equipment 
adapted from what was previous-
ly used for conventional packed 
bed chromatography processes. 
This technique shows improved 
washing and concentration of 
hMSCs compared to the previous 
TFF report [42], achieving higher 
recovery of viable hMSCs (89% 
compared to 70%) with no im-
pact on cell viability (95%) or 
other CQAs as mentioned in the 
last section.
Admittedly, with this tech-
nique, there are trade-offs to be 
made between cell recovery and 
protein clearance, but it can be 
efficiently integrated with al-
ready existing downstream pro-
cessing to improve washing ef-
ficiency up to 10-fold whilst 
maintaining high hMSC recov-
ery of 70% [50].
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TRANSLATIONAL INSIGHT
To bring cell-based therapies from 
bench to clinic, cost effective, 
scalable downstream processing 
techniques with high-resolution 
are required for integration into 
GMP-compatible bioprocessing 
platforms. Whilst this is the case for 
cellular therapies in general, it must 
be considered a particular priori-
ty for allogeneic therapies likely to 
be manufactured on larger scale for 
multiple recipients. Though various 
new cell selection methodologies 
described in this review are prom-
ising candidates that can achieve 
high purity and selectivity, at the 
current level of development trade-
off on various traits must usually 
be accepted. Many technologies are 
currently more suited as point-of-
care devices until further scalability 
has been addressed. Indeed, to date 
few can be seen to clearly perform 
better in terms of combined selec-
tivity and throughput than conven-
tional labeling methods. However, 
these established labeling methods 
do propose certain drawbacks that 
make them non-ideal for clinical 
applications. Moreover, due to their 
batch-type operation they do not 
lend themselves to be easily incor-
porated in integrated cell manufac-
turing system and may be limited in 
terms of scale of operation. As far as 
we are aware, the continuous centri-
fuge-based cell processing platforms 
described in this review as well as 
the later generation of acoustopher-
isis devices, are to date the only la-
bel-free commercial cell handling 
devices that have demonstrated 
processing of clinical grade cellular 
products in closed systems.
Undoubtedly, the reviewed 
methods will require further bioen-
gineering development and need to 
evolve from their current small-scale 
chip design to devices capable of 
high throughput to overcome the 
rate-limiting step – efficient cell se-
lection – of bringing regenerative 
medicine, and especially stem cell-
based therapeutics, to the patient. 
Given the number of methodolo-
gies under investigation, and the 
‘usual’ requirement in downstream 
bioprocessing to operate with mul-
tiple distinct separation steps, devel-
opment of hybrid devices; combin-
ing advantageous aspects of various 
methodologies, is likely to prove a 
useful approach. Lastly, due to the 
infancy of the cell therapy industry, 
disruptive technologies have a lot of 
potential as no technology has yet 
established itself as the gold-stan-
dard for the new products handled 
by this rapidly growing industry.
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